This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
« Back
Page 1 of 4

How to Evaluate Biotechs That Aren't Profitable Yet

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

07:50AM 01/24/02

This Earnings Season Could Be a Good One for Biotechs

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

07:27AM 01/17/02

Don't Write Off ImClone Just Yet

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

09:55AM 01/10/02

ImClone's Potential Could Be Worth the Risk

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

08:03AM 01/03/02

Biotech's Prognosis Improves at Year-End

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

07:58AM 12/27/01

The Amgen-Immunex Deal Is the Right Prescription

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

09:24AM 12/20/01

Protein Design Labs Is Still Worth Owning

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

08:34AM 12/13/01

Who Wins, Who Loses in the MedImmune-Aviron Deal

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

08:02AM 12/06/01

How to Play Stem-Cell Research Stocks

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

07:55AM 11/29/01

Some Biotech Mutual Funds Worth Considering

By Nadine Wong

Nadine Wong is the editor, publisher and co-founder of the monthly BioTech Sage Report. Wong writes a weekly column that appears on this page as part of her business relationship with TheStreet.com.

07:31AM 11/21/01

« Back
Page 1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,100.19 +62.22 0.34%
S&P 500 2,113.39 +4.47 0.21%
NASDAQ 5,058.40 -1.8460 -0.04%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs